Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Tumor 1Relapsed Solid Tumors 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1

Interventions

Octreotide 6Irinotecan 6Loperamide 5Probiotics 3Leucovorin 3Fluorouracil 3Fecal Microbiota Transplantation 3Calcium Aluminosilicate 3maltodextrin 2telotristat ethyl 1shosaiko-to 1lanreotide 1isatuximab 1ceterizine hydrochloride 1capivasertib 1cabazitaxel 1bile acid binding proteins 1XRP6258 1Theophylline 1Temozolomide 1Surveys and Questionnaires 1Sulfasalazine 1Sugars 1Standard of Care 1Raloxifene Hydrochloride 1Radiation 1Prednisone 1PHY 906 1Oxaliplatin 1Long-Term Synaptic Depression 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Diarrhea × Cefixime × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡